FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to specific derivatives of pyrrolidine-2-carboxamides specified in point 1 of the patent claim, and their pharmaceutically acceptable salts. The invention also refers to a pharmaceutical composition inhibiting the p53 and MDM2 reaction and to using the above compounds for treating cancer.
EFFECT: derivatives of pyrrolidine-2-carboxamide as p53 and MDM2 protein reaction inhibitors applicable for treating cancer.
11 cl, 475 ex
Title | Year | Author | Number |
---|---|---|---|
SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | 2009 |
|
RU2506257C2 |
COMBINED THERAPY BASED ON CD20 ANTIBODY COMBINED WITH BCL-2 INHIBITOR AND MDM2 INHIBITOR | 2016 |
|
RU2727196C2 |
LIGAND CONJUGATE WITH CYTOTOXIC DRUG PREPARATION, METHOD AND APPLICATION THEREOF | 2016 |
|
RU2708461C2 |
PYRROLIDINE DERIVATIVES AS NK-3 ANTAGONISTS | 2012 |
|
RU2598604C2 |
SPIROINDOLINONE PYRROLIDINES, USEFUL WHEN TREATING MALIGNANT GROWTHS | 2010 |
|
RU2571100C2 |
PYRROLIDINE DERIVATIVES | 2010 |
|
RU2562605C2 |
NOVEL CYCLOPENTANE DERIVATIVES | 2010 |
|
RU2572555C2 |
C-ARYL GLUCOSIDE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | 2011 |
|
RU2606501C2 |
MELANOCORTIN RECEPTOR AGONISTS | 2007 |
|
RU2411240C2 |
PYRROLIDINE DERIVATIVES AS NK-3 RECEPTOR ANTAGONISTS | 2010 |
|
RU2561271C2 |
Authors
Dates
2015-09-27—Published
2011-02-04—Filed